LUYAN PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 71.3236 million yuan, a decrease of 14.86%
LUYAN PHARMA released its Q1 2025 performance report, with operating revenue of 5.174 billion yuan, a year-on-year increase of 0.74%. The net profit attributable to the parent company was 71.3236 million yuan, a year-on-year decrease of 14.86%; the net profit after deducting non-recurring gains and losses was 70.8861 million yuan, a year-on-year decrease of 14.33%. The basic earnings per share were 0.18 yuan
According to the Zhitong Finance APP, LUYAN PHARMA (002788.SZ) released its first quarter report for 2025, with operating revenue of 5.174 billion yuan, a year-on-year increase of 0.74%. The net profit attributable to shareholders of the listed company was 71.3236 million yuan, a year-on-year decrease of 14.86%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 70.8861 million yuan, a year-on-year decrease of 14.33%. The basic earnings per share were 0.18 yuan
